Abstract 2580: Contrasting functions ofEPSTI1in human oral and lung squamous cell cancer cell lines - its tumor promoting roles in oral and tumor suppressing roles in lung squamous cell carcinomas

Purpose: As a member of the p53 family, p63 is considered to be an important differentiation regulation transcriptional factor, but the roles of p63 in many epithelial tumourigenesis and metastasis processes are still not clear. This study was designed to investigate the expression of p63 and its isoform in normal tissues and squamous cell cancer tissues of uterine cervix, and its significance in cancer cell differentiation. Methods: The expression of p63 was assessed in cervical tissue and cell lines by immunohistochemistry, RT-PCR and Western Blotting. The relationships between p63 protein, various clinico-pathological features, and the differentiation marker involucrin were analyzed. Results: ΔΝp63α is the predominant isoform expressed in cervical epithelial tissues, and it is decreased in moderately or poorly differentiated cervical squamous carcinoma, as well as in the HeLa, SiHa and C33A cervical cancer cell lines. The expression level of ΔΝp63α was positively correlated with that of involucrin in cervical squamous cancer tissue, and the expression of ΔΝp63α is decreased with the degree of tumour invasion. Conclusion: The decrease of ΔΝp63α in cervical squamous cell cancer appears to be associated with the tumour progression, and ΔΝp63α may be a sensitive marker for cervical squamous cancer differentiation.

Download Full-text

Mutation and aberrant expression of Caveolin-1 in human oral squamous cell carcinomas and oral cancer cell lines

International Journal of Oncology ◽

10.3892/ijo.24.2.435 ◽

2004 ◽

Cited By ~ 3

Author(s):

Song Han ◽

Kyung-Hee Park ◽

Gene Lee ◽

Yoon-Jeong Huh ◽

Byung-Moo Min

Keyword(s):

Oral Cancer ◽

Cell Lines ◽

Cancer Cell ◽

Squamous Cell ◽

Cancer Cell Lines ◽

Squamous Cell Carcinomas ◽

Aberrant Expression ◽

Oral Squamous Cell Carcinomas ◽

Caveolin 1 ◽

Oral Cancer Cell

Download Full-text

Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hürthle Cell Cancer

Cancers ◽

10.3390/cancers11081185 ◽

2019 ◽

Vol 11 (8) ◽

pp. 1185 ◽

Cited By ~ 1

Author(s):

Mehtap Derya Aydemirli ◽

Willem Corver ◽

Ruben Beuk ◽

Paul Roepman ◽

Nienke Solleveld-Westerink ◽

...

Keyword(s):

Thyroid Cancer ◽

Cell Lines ◽

Cancer Cell ◽

Treatment Options ◽

Cell Cancer ◽

Control Cell ◽

Single Agent ◽

Cancer Cell Lines ◽

Akt Signaling ◽

Hürthle Cell

Objective: To evaluate the efficacy and treatment rationale of Hürthle cell carcinoma (HCC) following a patient with progressive and metastatic HCC. HCC was recently shown to harbor a distinct genetic make-up and the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kiase (PI3K)/AKT signaling pathways are potential targets for anti-cancer agents in the management of recurrent HCC. The presence or absence of gene variants can give a rationale for targeted therapies that could be made available in the context of drug repurposing trials. Methods: Treatment included everolimus, sorafenib, nintedanib, lenvatinib, and panitumumab. Whole genome sequencing (WGS) of metastatic tumor material obtained before administration of the last drug, was performed. We subsequently evaluated the rationale and efficacy of panitumumab in thyroid cancer and control cell lines after epidermal growth factor (EGF) stimulation and treatment with panitumumab using immunofluorescent Western blot analysis. EGF receptor (EGFR) quantification was performed using flow cytometry. Results: WGS revealed a near-homozygous genome (NHG) and a somatic homozygous TSC1 variant, that was absent in the primary tumor. In the absence of RAS variants, panitumumab showed no real-life efficacy. This might be explained by high constitutive AKT signaling in the two thyroid cancer cell lines with NHG, with panitumumab only being a potent inhibitor of pEGFR in all cancer cell lines tested. Conclusions: In progressive HCC, several treatment options outside or inside clinical trials are available. WGS of metastatic tumors might direct the timing of therapy. Unlike other cancers, the absence of RAS variants seems to provide insufficient justification of single-agent panitumumab administration in HCC cases harboring a near-homozygous genome.

Download Full-text